We suggest that because of the larger number of such reported cases of this disease, USP53-associated cholestasis can be confirmed as a valid disease and should, therefore, be included in the liver gene panels which will further increase the effectiveness of molecular genetic studies. This evidence concerns the gene USP53 and cholestasis.